<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This is one of the first studies to report on therapeutic drug monitoring (TDM) of posaconazole (PCZ) for antifungal prophylaxis in patients with <z:hpo ids='HP_0011009'>acute</z:hpo> myelogenous <z:mpath ids='MPATH_336'>leukaemia</z:mpath> or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> outside of the rigours of clinical licencing trials </plain></SENT>
<SENT sid="1" pm="."><plain>A number of factors have been identified or proposed as causing poor oral absorption of PCZ </plain></SENT>
<SENT sid="2" pm="."><plain>Putative PCZ concentrations have been recommended for TDM (0.5 μg/mL or 0.7 μg/mL) </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, 19 (90.5%) of 21 patients failed to reach the higher putative target of 0.7 μg/mL, and 16 patients (76.2%) failed to reach the lower target of 0.5 μg/mL </plain></SENT>
<SENT sid="4" pm="."><plain>Increasing the dose did not help four of six patients reach target concentrations </plain></SENT>
<SENT sid="5" pm="."><plain>Three of the patients developed 'proven' or 'possible' <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infections</z:e>, <z:hpo ids='HP_0000001'>all</z:hpo> with PCZ concentrations &lt;0.5 μg/mL </plain></SENT>
<SENT sid="6" pm="."><plain>Use of acid-suppressing agents appears to explain some of the poor absorption </plain></SENT>
<SENT sid="7" pm="."><plain>TDM of PCZ is warranted in patients receiving this orally administered agent </plain></SENT>
</text></document>